{"classes":[{"categories":[{"measurements":[{"comment":"Here, 'NA' signifies that mean and standard deviation could not be calculated as concentration was below quantification limit (\\<0.500 ng/mL).","groupId":"OG000","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"Predose Day 1 Week 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.97","value":"3.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"Predose Day 1 Week 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.36","value":"6.27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"Predose Day 1 Week 9"}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Plasma concentrations of ibrutinib were reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed or refractory waldenstrom's macroglobulinemia received ibrutinib 420 milligrams (mg) (3\\*140 mg capsules) orally once daily from Day 1 of Week 1 until disease progression, unacceptable toxicity, whichever occurs first.","id":"OG000","title":"Ibrutinib 420 mg"}],"paramType":"MEAN","populationDescription":"Pharmacokinetics (PK) evaluable analysis set included all enrolled participants who received at least 1 dose of ibrutinib and had at least 1 available PK sample after treatment. Here, 'n' (number analyzed) signifies number of participants evaluable for specified time point.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 1 of Weeks 1, 5 and 9","title":"Plasma Concentration of Ibrutinib","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter (ng/mL)"}